We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Thames Ventures Vct 2 Plc | LSE:D467 | London | Ordinary Share | GB00BWX53D91 | DP67 ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.00 | 9.00 | 19.00 | 14.00 | 14.00 | 14.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | -6.02M | -7.66M | -0.0777 | -12.81 | 98.05M |
Hot Features
Premium
TIDMD467
Downing FOUR VCT plc (the "Company")
LEI: 21380035MV1VRYEXPR95
3 June 2021
Portfolio Update
The Directors of the Company are pleased to report that Generalist and
Healthcare Share portfolio company, Arecor Therapeutics ("Arecor"), has
today had its ordinary shares admitted to trading on AIM. The admission
follows a successful GBP20.0 million placing of new shares at a price of
226 pence per ordinary share (the "placing price").
Based on the placing price, the values of the Company's Generalist and
Healthcare Share pools' holdings in Arecor have increased by
approximately 0.9p per Generalist Share and 8.0p per Healthcare Share.
This is equivalent to increases of 1.3% and 11.4% in the unaudited NAVs
of the Generalist and Healthcare Share pools respectively, as at 28
February 2021 (being the most recent NAVs announced by the Company).
Enquiries:
Grant Whitehouse
Downing LLP
Company Secretary
020 7630 4333
(END) Dow Jones Newswires
June 03, 2021 10:42 ET (14:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Thames Ventures Vct 2 Chart |
1 Month Thames Ventures Vct 2 Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
